Page last updated: 2024-10-26

dipyridamole and Hemangioma, Cavernous, Central Nervous System

dipyridamole has been researched along with Hemangioma, Cavernous, Central Nervous System in 1 studies

Dipyridamole: A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752)
dipyridamole : A pyrimidopyrimidine that is 2,2',2'',2'''-(pyrimido[5,4-d]pyrimidine-2,6-diyldinitrilo)tetraethanol substituted by piperidin-1-yl groups at positions 4 and 8 respectively. A vasodilator agent, it inhibits the formation of blood clots.

Hemangioma, Cavernous, Central Nervous System: A vascular anomaly composed of a collection of large, thin walled tortuous VEINS that can occur in any part of the central nervous system but lack intervening nervous tissue. Familial occurrence is common and has been associated with a number of genes mapped to 7q, 7p and 3q. Clinical features include SEIZURES; HEADACHE; STROKE; and progressive neurological deficit.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Flemming, KD1
Link, MJ1
Christianson, TJ1
Brown, RD1

Other Studies

1 other study available for dipyridamole and Hemangioma, Cavernous, Central Nervous System

ArticleYear
Use of antithrombotic agents in patients with intracerebral cavernous malformations.
    Journal of neurosurgery, 2013, Volume: 118, Issue:1

    Topics: Aged; Aspirin; Cerebral Hemorrhage; Dipyridamole; Female; Fibrinolytic Agents; Follow-Up Studies; He

2013